Tyrosine phenol lyase mutant, nucleotide, vector, host and application thereof
By mutation of specific amino acid sites of tyrosine phenol lyase, the activity and substrate tolerance of enzymes are improved, and the problems of low enzyme activity and insufficient tolerance in enzyme catalysis are solved, thus achieving high efficiency of levodopa Synthesis, suitable for industrial applications.
Patent Information
- Application Number
- CN202411106029.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-12
AI Technical Summary
In the synthesis of levodopa, the enzyme activity is low and the substrate tolerance is not strong, resulting in high cost of using enzymes, long reaction time, and limited conversion rate, making it difficult to meet the needs of industrial applications.
Mutation screening of tyrosine phenol lyase with Floranuci can improve enzyme activity and substrate tolerance, including mutations in amino acid sites A26V, R145C, E147V, E425D, and P357S to form higher vitality enzyme mutants used to catalyze the synthesis of levodopa.
The enzyme activity of mutant enzymes is increased by about 3 times, substrate tolerance is significantly enhanced, reaction time is shortened, unit yield is increased, and conversion rate reaches 93.3%, which is more suitable for industrial applications.
Smart Images

Figure CN118931890A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of enzyme engineering and relates to a tyrosine phenol lyase mutant, nucleotides, a carrier and applications thereof. Background Art
[0002] L-DOPA, also known as 3-hydroxy-L-tyrosine, 3-(3,4-Dihydroxyphenyl)-L-alanine, is currently the main drug for the treatment of Parkinson's syndrome. It can pass through the blood-brain barrier and reach the central nervous system. Under the action of decarboxylase in the body, it is converted into dopamine, thereby playing a role in treating Parkinson's syndrome. In addition, studies have also found that L-DOPA can also treat dystonia, heart failure, schizophrenia, amblyopia, etc. With the increasing application of L-DOPA in the medical and health fields, its demand is also increasing.
[0003] At present, the main synthesis methods of L-DOPA are plant extraction, chemical synthesis and enzyme catalysis. Plant extraction is less used due to the limitation of raw material sources. Although chemical synthesis has been used for commercialization, there are many synthesis steps (such as using vanillin and hydantoin as raw materials, it takes 8 steps to produce L-DOPA), a large amount of metal catalysts, and serious problems such as high cost and high pollution. Bioenzyme catalysis has attracted more and more attention from researchers as a simple, efficient and environmentally friendly new synthesis method.
[0004] In the bio-enzyme method, tyrosine phenol lyase (Fn-TPL) derived from Fusobacterium nucleatum has the highest yield of synthetic levodopa. However, the substrate catechol is not a natural substrate of the enzyme. And high concentrations of catechol will have a toxic effect on enzymes and cells, and even irreversibly inactivate the enzyme, ultimately inhibiting the synthesis of levodopa. Therefore, there are still problems such as low enzyme activity, weak substrate (catechol) tolerance, and high enzyme cost. At present, research mainly focuses on the improvement of enzyme activity, such as CN 113980948 B and CN 114250237B, which improve the activity of TPL after transformation by 1.53-3.2 times, but due to the weak substrate tolerance, multiple batches of feed reactions are required, resulting in a reaction time of up to 36h, and a conversion rate of about 90%, and a levodopa accumulation of 146g / L, and there is room for further improvement.
[0005] Therefore, enhancing the tolerance of enzymes to substrates while improving enzyme activity is an urgent problem to be solved in biocatalysis. Based on this purpose, the present invention uses tyrosine phenol lyase (Fn-TPL) from Fusobacterium nucleatum for mutation screening, further improving enzyme activity, substrate tolerance and yield. The enzyme cost and reaction time are significantly reduced, and the unit yield is further increased, making it more suitable for industrial applications. Summary of the invention
[0006] The primary purpose of the present invention is to provide a tyrosine phenol lyase mutant, so that the mutant has higher enzyme activity, substrate tolerance and yield than the wild-type tyrosine phenol lyase, making it more suitable for industrial application.
[0007] To achieve this object, in a basic embodiment, the present invention provides a tyrosine phenol lyase mutant, which is a mutation of the amino acid sequence shown in SEQ ID NO.1, and the mutated amino acid site is at least one of A26V, R145C, E147V, E425D, and P357S.
[0008] Furthermore, the mutant includes any one of the following 7 types:
[0009] A26V; R145C; P357S; E147V+E425D; E147V+E425D+A26V;
[0010] E147V+E425D+R145C; E147V+E425D+P357S;
[0011] Preferred:
[0012] Any one of E147V+E425D, E147V+E425D+A26V, A26V, E147V+E425D+P357S;
[0013] Further preferred: E147V+E425D or E147V+E425D+A26V.
[0014] The second object of the present invention is to provide a polynucleotide encoding the aforementioned tyrosine phenol lyase mutant, so that the encoded tyrosine phenol lyase mutant has higher activity and conversion rate than the wild-type tyrosine phenol lyase, making it more suitable for industrial application.
[0015] The third object of the present invention is to provide a vector containing the polynucleotide of the tyrosine phenol lyase mutant.
[0016] The fourth object of the present invention is to provide a host, such as a strain, containing the vector.
[0017] The fifth object of the present invention is to provide the application of the tyrosine phenol lyase mutant: for catalyzing the preparation of levodopa.
[0018] To achieve this object, in a basic embodiment, the present invention provides an application of a tyrosine phenol-lyase mutant, wherein the application is to use the aforementioned tyrosine phenol-lyase mutant to catalyze the preparation of levodopa in a reaction system.
[0019] Furthermore, in every 500 mL reaction system, the amount of crude tyrosine phenol lyase solution added is 20-60 g / L, and the corresponding enzyme activity is 3000-9000 U.
[0020] Furthermore, in the reaction system, the concentration of PLP is 0.1-0.2 g / L, the concentration of sodium sulfite is 0.5-6 g / L, the concentration of ammonium acetate is 50-280 g / L, the concentration of sodium pyruvate is 40-220 g / L, the concentration of catechol is 40-220 g / L, and the concentration of disodium EDTA is 1-2 g / L.
[0021] Furthermore, the reaction temperature is 20-30°C, and the reaction time is 5-22h.
[0022] Furthermore, the reaction pH is 7.5-8.5.
[0023] Furthermore, the reaction stirring speed is 150-200r / min.
[0024] The beneficial effect of the present invention is that the fermentation activity of the mutant is about 3 times higher than that of the wild-type tyrosine phenol lyase, and the tolerance to the substrate catechol is significantly improved compared with the control, the yield reaches about 200 g / L within 21 hours, and the yield rate reaches 93.3%. Compared with the mutant strain reported, the mutant strain of the present invention further improves the tolerance of the enzyme to the substrate while improving the enzyme activity to a considerable extent, so that the reaction can be carried out at a higher concentration, and the reaction time is significantly shortened, and the unit yield is increased. It is more suitable for industrial applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 Schematic diagram of the reaction of tyrosine phenol lyase catalyzing the synthesis of L-DOPA. DETAILED DESCRIPTION
[0026] The present invention is further described below in conjunction with the embodiments, but is not limited thereto.
[0027] The method for determining the enzyme activity of tyrosine phenol lyase and its mutants is as follows.
[0028] Substrate solution preparation:
[0029] Accurately weigh 1.5 g of catechol, 1.8 g of sodium pyruvate, 3 g of ammonium acetate, 50 mg of PLP, 0.3 g of sodium sulfite, and 0.4 g of disodium EDTA, add 90 mL of 0.1 mol / L pH 8.5 Tris-HCl buffer, adjust the pH to 8.5 with 1 mol / L sodium hydroxide solution, and then make up to 100 mL with buffer.
[0030] Viability assay:
[0031] Dilute the sample with saline to 5-16U / mL, take 1mL to a 50mL test tube, add 4mL 0.87% saline, keep it in a constant temperature water bath at 25℃, add 10mL preheated substrate solution to react for 10min, add 3mL 25% trichloroacetic acid to terminate the reaction. Centrifuge and take 1mL supernatant to a 50mL volumetric flask, dilute to 50mL with mobile phase, and perform HPLC analysis.
[0032] HPLC analysis conditions:
[0033] Mobile phase: Dissolve 5.7g of ammonium dihydrogen phosphate in 1000mL of water, adjust the pH to 3.5 with phosphoric acid, filter, take 950mL, add 50mL of methanol, shake well and degas.
[0034] Column temperature: 25°C
[0035] Flow rate: 1mL / min
[0036] Wavelength: 210mn
[0037] Running time: 20 minutes
[0038] The enzyme activity was defined as: the amount of enzyme that converts 1 micromole of L-DOPA per minute at 25°C and pH 8.5 was defined as 1 unit (1U).
[0039] Example 1: Construction of prokaryotic expression strain of tyrosine phenol lyase
[0040] The amino acid sequence of tyrosine phenol lyase (Fn-TPL) from Fusobacterium nucleatum was downloaded from GenBank (SEQ ID NO.1 in this article, corresponding to GenBank accession number: WP_011015962) and provided to General Bio (Anhui) Co., Ltd. for full gene synthesis of the encoding nucleic acid (using Escherichia coli preferred codons). It was constructed into the prokaryotic expression vector pET30a (+), and the prokaryotic expression vector restriction sites were: Nde I at the 5' end and Xho I at the 3' end. The constructed plasmid pET30a (+)-TPL was transformed into the Escherichia coli expression strain BL21 (DE3) by CaCl2 heat shock transformation method, coated on LB solid culture medium plates containing 50 μg / mL Kanamycin, and cultured at 37°C overnight. The colonies grown on the plates were the prokaryotic expression recombinant strain E. coli BL21 (DE3) / pET30a (+)-TPL of tyrosine phenol lyase.
[0041] Fermentation of recombinant strains: Carefully pick a single colony of the TPL prokaryotic expression recombinant strain from the above LB solid medium plate with a sterilized pipette tip, inoculate it into a flask containing 20 mL of LB liquid medium, and culture it at 37°C, 200 r / min, shaking overnight. The next day, inoculate the shake flask culture liquid into a flask containing 100 mL of TB liquid medium at 1% inoculation volume, and culture it at 37°C, 220 r / min, shaking, and measure the OD of the culture liquid every 1 hour. 600 When the OD value of the culture solution reached 1.5, lactose was added at a final concentration of 1% (m / v), and the culture was continued at 25°C and 220 rpm for 4h-6h. The culture was stopped to obtain the fermentation solution.
[0042] Example 2: Construction of TPL prokaryotic expression strain E. coli BL21 (DE3) / pET30a (+) -TPL error-prone mutation library
[0043] The pET30a(+)-TPL recombinant plasmid was used as the PCR template and conventional T7F / R as universal primers (primer sequence: T7F: 5'-TAATACGACTCACTATAGGG-3'T7R: GCTAGTTATTGCTCAGCGG) were used to perform error-prone PCR amplification of the TPL gene. The Mg content in the PCR amplification reaction system was adjusted. 2+ , Mn 2+ , dCTP and dTTP oligonucleotide concentrations so that the base mismatch rate of the mutant library is only 0.2%, which ensures that only 1 to 2 amino acids are mutated in a mutant.
[0044] Error-prone PCR reaction system:
[0045]
[0046]
[0047] Error-prone PCR reaction conditions: first pre-denaturation at 95°C for 5 minutes; then denaturation at 94°C for 30 seconds, annealing at 56°C for 30 seconds, and extension at 72°C for 1 minute, for a total of 25 cycles; finally extension at 72°C for 10 minutes.
[0048] 2 μL of the error-prone PCR product was sampled for agarose gel electrophoresis detection, and after the detection was correct, it was purified using a PCR product purification kit. Under 37°C, the PCR purified product and the prokaryotic expression vector pET30a(+) were double-digested with Nde I and Xho I restriction endonucleases, respectively, and the enzyme digestion products were recovered by gel cutting (wherein the size of the recovered PCR purified product fragment was about 1300 bp, and the size of the recovered vector pET30a(+) fragment was about 5300 bp). After that, the error-prone PCR product: prokaryotic expression vector pET30a(+) was mixed at a molar ratio of 3:1, and T4 DNA ligase was added to connect at 16°C overnight. On the next day, the ligation product was transferred into Escherichia coli BL21(DE3) by electroporation to construct an engineering bacterium, and a random mutant library with a large library capacity was obtained.
[0049] Example 3: Screening of TPL prokaryotic expression strain E. coli BL21 (DE3) / pET30a (+) -TPL mutant library
[0050] Single colonies were picked from the TPL mutant library with a sterile toothpick and cultured in a 96-well deep plate, each well containing 320 μL of LB medium supplemented with 50 μg / mL kanamycin. The plate was placed in a constant temperature shaker (240 rpm) and cultured at 37°C for 8 hours. Then, 20 μL of the culture was transferred to a new 96-well microplate containing 10% glycerol (v / v) as a daughter plate and stored at 4°C. After preparing the daughter plate, 20 μL, 10% (w / v) lactose was added to the mother plate, and the plate was incubated at 25°C overnight to induce the expression of the target protein. Subsequently, 200 μL of the induced expression bacterial solution was centrifuged and the supernatant was removed and added to a 96-well microtiter plate containing 100 μL of lysis buffer (0.1% (v / v) Triton X-100, 0.5 mg / mL lysozyme, 0.1 mol / L Tris-HCl buffer at pH 8.5) and mixed. After incubation at 30°C for 1 hour, the cell lysis mixture was centrifuged at 4000 rpm at 4°C for 10 minutes, and the supernatant was the crude enzyme solution for TPL activity determination.
[0051] Preparation of high-throughput screening reaction solution: weigh 1.54 g of catechol, 1.86 g of sodium pyruvate, 3.06 g of ammonium acetate, 31.56 mg of pyridoxal phosphate (PLP), 0.44 g of sodium sulfite, and 0.18 g of disodium EDTA, and add 0.1 mol / L, pH 8.5 Tris-HCl buffer to make up to 50 mL.
[0052] The high-throughput screening method is to take 50uL of the above crude enzyme solution and add it to 50uL of the reaction solution to react at 30°C. After 1 hour, add 50uL of 1M HCl to terminate the reaction, centrifuge and take 50uL of the supernatant, add 25uL of 5M sodium hydroxide, add 25uL of 2% salicylaldehyde, and observe the color change.
[0053] Through repeated large-scale screening and verification (about 100,000 clones), sequencing analysis and enzyme activity determination, four strains with higher activity than the wild type were screened. They were named TPL-1, TPL-2, TPL-3, and TPL-4. Their mutation sites and activity are shown in Table 1. TPL-3 with the highest activity was used as the template for the next test.
[0054] Table 1 TPL error-prone library screening
[0055] Enzymes Mutation site Activity U / mL TPL-WT 4.76 TPL-1 A26V 6.95 TPL-2 R145C 8.04 TPL-3 E147V+E425D 11.02 TPL-4 P357S 7.68
[0056] Example 4: Construction of TPL-3 prokaryotic expression strain E. coli BL21(DE3) / pET30a(+)-TPL-3 superimposed mutant strain
[0057] The pET30a(+)-TPL-3 recombinant plasmid was used as a PCR template to superimpose the mutation sites in TPL-1, TPL-2, and TPL-4. They were named TPL-5, TPL-6, and TPL-7, respectively. Their activity is shown in Table 2. A better mutant strain TPL-5 was obtained.
[0058] Table 2 Mutation superposition using TPL-3 as template
[0059] Enzymes Mutation site Activity U / mL TPL-WT 4.76 TPL-1 A26V 6.95 TPL-2 R145C 8.04 TPL-3 E147V+E425D 11.02 TPL-4 P357S 7.68 TPL-5 E147V+E425D+A26V 13.81 TPL-6 E147V+E425D+R145C 8.70 TPL-7 E147V+E425D+P357S 8.62
[0060] Example 5: Comparison of the reaction of mutant strain and control strain TPL-WT in catalyzing the synthesis of levodopa
[0061] After the above 7 mutant strains and TPL-WT were collected by shaking flask, they were prepared into a bacterial solution with a bacterial concentration of 400 g / L using physiological saline, and ultrasonically broken to obtain a crude enzyme solution for use. The weight of bacteria in the bacterial solution was determined by first weighing the empty bottle weight of a 500 ml centrifuge bottle, adding the bacterial solution and centrifuging at 8000 rpm for 10 minutes, removing the supernatant, and weighing again. The difference between the empty bottle weight and the weight of the empty bottle was the bacterial weight.
[0062] Reaction conditions: 500mL system
[0063]
[0064] Note: Sodium pyruvate, catechol and sodium sulfite are dissolved and added into the system by feeding method.
[0065] Table 3 Comparison of the reaction of mutant strain and control strain TPL-WT in catalyzing the synthesis of L-dopa
[0066] Enzymes 6h conversion yield Final conversion time Final conversion yield TPL-WT 61.13% 12 92.98% TPL-1 66.20% 11 94.12% TPL-2 48.74% 12 87.83% TPL-3 89.35% 8 95.66% TPL-4 63.56% 12 91.26% TPL-5 98.57% 6 98.57% TPL-6 57.47% 12 92.11% TPL-7 72.89% 10 93.37%
[0067] Example 6: Comparison of substrate catechol tolerance
[0068] Take the crude enzyme solution, add catechol to make the final concentration of catechol in the enzyme solution 0.5%-2%, and add the corresponding proportion of sodium sulfite in Example 5 at the same time. After standing at 25°C for 30 minutes, the enzyme activity is detected and the residual enzyme activity rate is calculated. As shown in Table 4 below, under the condition of low concentration of catechol, the enzyme has no activity loss. As the concentration of catechol increases, the enzyme activity loss gradually increases. However, the overall inactivation rate of the mutant strain is significantly lower than that of the control.
[0069] Table 4 Residual enzyme activity after 30 min treatment with different concentrations of catechol
[0070]
[0071]
[0072] Example 7: Comparison of high concentration substrate conversion
[0073] The superior mutant strains TPL-3, TPL-5 and TPL-WT with significantly improved performance were subjected to high-concentration substrate conversion. Referring to the reaction conditions in Example 5, the concentration of catechol was increased to 210 g / L, and the concentrations of sodium pyruvate, sodium sulfite and ammonium acetate were increased in the same proportion. The reaction was started after adding bacteria with the same enzyme activity. As shown in Table 5 below, the best mutant strain TPL-5 completed the conversion within 21 hours, and the conversion yield was 93.3%, which was higher than TPL-3 and significantly higher than TPL-WT.
[0074] Table 5 Comparison of high concentration substrate conversion
[0075] Enzymes Reaction time Bacterial dosage (g / L) Final conversion yield TPL-WT 21h 58 38.77% TPL-3 21h 25 82.46% TPL-5 21h 20 93.30%
[0076] As can be seen from the above examples, the improvement of enzyme activity and the improvement of enzyme tolerance to substrate can significantly shorten the reaction time or improve the reaction yield. The best mutant strain TPL-5 takes less time, has a higher conversion yield, and can tolerate higher substrate concentrations. Compared with the mutant strains reported, the mutant strain of the present invention further improves the enzyme tolerance to substrates while improving the enzyme activity, so that the reaction can be carried out at a higher concentration, and significantly shortens the reaction time, and improves the unit yield.
[0077] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these changes and variations. The above embodiments or implementations are merely illustrative of the present invention, and the present invention may also be implemented in other specific ways or other specific forms without departing from the gist or essential features of the present invention. Therefore, the described implementations should be considered illustrative rather than restrictive in any respect. The scope of the present invention should be described by the appended claims, and any changes equivalent to the intent and scope of the claims should also be included within the scope of the present invention.
[0078] Sequence Listing
[0079] TPL (SEQ ID NO.1)
[0080] MRFEDYPAEPFRIKSVETVKMIDKAAREEVIKKAGYNTFLINSEDVYIDLLTDSGTNAMSDKQWGGLMQ
[0081] GDEAYAGSRNFFHLEETVKEIFGFKHIVPTHQGRGAENILSQIAIKPGQYVPGNMYFTTTRYHQERNGG
[0082] IFKDIIRDEAHDATLNVPFKGDIDLNKLQKLIDEVGAENIAYVCLAVTVNLAGGQPVSMKNMKAVRELT
[0083] KKHGIKVFYDATRCVENAYFIKEQEEGYQDKTIKEIVHEMFSYADGCTMSGKKDCLVNIGGFLCMNDED
[0084] LFLAAKEIVVVYEGMPSYGGLAGRDMEAMAIGLRESLQYEYIRHRILQVRYLGEKLKEAGVPILEPVGG
[0085] HAVFLDARRFCPHIPQEEFPAQALAAAIYVECGVRTMERGIISAGRDVKTGENHKPKLETVRVTIPRRVYTYKHMDVVAEGIIKLYKHKEDIKPLEFVYEPKQLRFFTARFGIKK*
[0086] TPL-1 (SEQ ID NO. 2)
[0087] MRFEDYPAEPFRIKSVETVKMIDKAVREEVIKKAGYNTFLINSEDVYIDLLTDSGTNAMSDKQWGGLMQ
[0088] GDEAYAGSRNFFHLEETVKEIFGFKHIVPTHQGRGAENILSQIAIKPGQYVPGNMYFTTTRYHQERNGG
[0089] IFKDIIRDEAHDATLNVPFKGDIDLNKLQKLIDEVGAENIAYVCLAVTVNLAGGQPVSMKNMKAVRELT
[0090] KKHGIKVFYDATRCVENAYFIKEQEEGYQDKTIKEIVHEMFSYADGCTMSGKKDCLVNIGGFLCMNDED
[0091] LFLAAKEIVVVYEGMPSYGGLAGRDMEAMAIGLRESLQYEYIRHRILQVRYLGEKLKEAGVPILEPVGG
[0092] HAVFLDARRFCPHIPQEEFPAQALAAAIYVECGVRTMERGIISAGRDVKTGENHKPKLETVRVTIPRRVYTYKHMDVVAEGIIKLYKHKEDIKPLEFVYEPKQLRFFTARFGIKK*
[0093] TPL-2(SEQ ID NO.3)
[0094] MRFEDYPAEPFRIKSVETVKMIDKAAREEVIKKAGYNTFLINSEDVYIDLLTDSGTNAMSDKQWGGLMQ
[0095] GDEAYAGSRNFFHLEETVKEIFGFKHIVPTHQGRGAENILSQIAIKPGQYVPGNMYFTTTRYHQERNGG
[0096] IFKDIICDEAHDATLNVPFKGDIDLNKLQKLIDEVGAENIAYVCLAVTVNLAGGQPVSMKNMKAVRELT
[0097] KKHGIKVFYDATRCVENAYFIKEQEEGYQDKTIKEIVHEMFSYADGCTMSGKKDCLVNIGGFLCMNDED
[0098] LFLAAKEIVVVYEGMPSYGGLAGRDMEAMAIGLRESLQYEYIRHRILQVRYLGEKLKEAGVPILEPVGG
[0099] HAVFLDARRFCPHIPQEEFPAQALAAAIYVECGVRTMERGIISAGRDVKTGENHKPKLETVRVTIPRRVYTYKHMDVVAEGIIKLYKHKEDIKPLEFVYEPKQLRFFTARFGIKK*
[0100] TPL-3(SEQ ID NO.4)
[0101] MRFEDYPAEPFRIKSVETVKMIDKAAREEVIKKAGYNTFLINSEDVYIDLLTDSGTNAMSDKQWGGLMQ
[0102] GDEAYAGSRNFFHLEETVKEIFGFKHIVPTHQGRGAENILSQIAIKPGQYVPGNMYFTTTRYHQERNGG
[0103] IFKDIIRDVAHDATLNVPFKGDIDLNKLQKLIDEVGAENIAYVCLAVTVNLAGGQPVSMKNMKAVRELT
[0104] KKHGIKVFYDATRCVENAYFIKEQEEGYQDKTIKEIVHEMFSYADGCTMSGKKDCLVNIGGFLCMNDED
[0105] LFLAAKEIVVVYEGMPSYGGLAGRDMEAMAIGLRESLQYEYIRHRILQVRYLGEKLKEAGVPILEPVGG
[0106] HAVFLDARRFCPHIPQEEFPAQALAAAIYVECGVRTMERGIISAGRDVKTGENHKPKLETVRVTIPRRVYTYKHMDVVADGIIKLYKHKEDIKPLEFVYEPKQLRFFTARFGIKK*
[0107] TPL-4(SEQ ID NO.5)
[0108] MRFEDYPAEPFRIKSVETVKMIDKAAREEVIKKAGYNTFLINSEDVYIDLLTDSGTNAMSDKQWGGLMQ
[0109] GDEAYAGSRNFFHLEETVKEIFGFKHIVPTHQGRGAENILSQIAIKPGQYVPGNMYFTTTRYHQERNGG
[0110] IFKDIIRDEAHDATLNVPFKGDIDLNKLQKLIDEVGAENIAYVCLAVTVNLAGGQPVSMKNMKAVRELT
[0111] KKHGIKVFYDATRCVENAYFIKEQEEGYQDKTIKEIVHEMFSYADGCTMSGKKDCLVNIGGFLCMNDED
[0112] LFLAAKEIVVVYEGMPSYGGLAGRDMEAMAIGLRESLQYEYIRHRILQVRYLGEKLKEAGVPILEPVGG
[0113] HAVFLDARRFCSHIPQEEFPAQALAAAIYVECGVRTMERGIISAGRDVKTGENHKPKLETVRVTIPRRVYTYKHMDVVAEGIIKLYKHKEDIKPLEFVYEPKQLRFFTARFGIKK*
[0114] TPL-5(SEQ ID NO.6)
[0115] MRFEDYPAEPFRIKSVETVKMIDKAVREEVIKKAGYNTFLINSEDVYIDLLTDSGTNAMSDKQWGGLMQ
[0116] GDEAYAGSRNFFHLEETVKEIFGFKHIVPTHQGRGAENILSQIAIKPGQYVPGNMYFTTTRYHQERNGG
[0117] IFKDIIRDVAHDATLNVPFKGDIDLNKLQKLIDEVGAENIAYVCLAVTVNLAGGQPVSMKNMKAVRELT
[0118] KKHGIKVFYDATRCVENAYFIKEQEEGYQDKTIKEIVHEMFSYADGCTMSGKKDCLVNIGGFLCMNDED
[0119] LFLAAKEIVVVYEGMPSYGGLAGRDMEAMAIGLRESLQYEYIRHRILQVRYLGEKLKEAGVPILEPVGG
[0120] HAVFLDARRFCPHIPQEEFPAQALAAAIYVECGVRTMERGIISAGRDVKTGENHKPKLETVRVTIPRRVYTYKHMDVVADGIIKLYKHKEDIKPLEFVYEPKQLRFFTARFGIKK*
[0121] TPL-6(SEQ ID NO.7)
[0122] MRFEDYPAEPFRIKSVETVKMIDKAAREEVIKKAGYNTFLINSEDVYIDLLTDSGTNAMSDKQWGGLMQ
[0123] GDEAYAGSRNFFHLEETVKEIFGFKHIVPTHQGRGAENILSQIAIKPGQYVPGNMYFTTTRYHQERNGG
[0124] IFKDIICDVAHDATLNVPFKGDIDLNKLQKLIDEVGAENIAYVCLAVTVNLAGGQPVSMKNMKAVRELT
[0125] KKHGIKVFYDATRCVENAYFIKEQEEGYQDKTIKEIVHEMFSYADGCTMSGKKDCLVNIGGFLCMNDED
[0126] LFLAAKEIVVVYEGMPSYGGLAGRDMEAMAIGLRESLQYEYIRHRILQVRYLGEKLKEAGVPILEPVGG
[0127] HAVFLDARRFCPHIPQEEFPAQALAAAIYVECGVRTMERGIISAGRDVKTGENHKPKLETVRVTIPRRVYTYKHMDVVADGIIKLYKHKEDIKPLEFVYEPKQLRFFTARFGIKK*
[0128] TPL-7 (SEQ ID NO.8)
[0129] MRFEDYPAEPFRIKSVETVKMIDKAAREEVIKKAGYNTFLINSEDVYIDLLTDSGTNAMSDKQWGGLMQ
[0130] GDEAYAGSRNFFHLEETVKEIFGFKHIVPTHQGRGAENILSQIAIKPGQYVPGNMYFTTTRYHQERNGG
[0131] IFKDIIRDVAHDATLNVPFKGDIDLNKLQKLIDEVGAENIAYVCLAVTVNLAGGQPVSMKNMKAVRELT
[0132] KKHGIKVFYDATRCVENAYFIKEQEEGYQDKTIKEIVHEMFSYADGCTMSGKKDCLVNIGGFLCMNDED
[0133] LFLAAKEIVVVYEGMPSYGGLAGRDMEAMAIGLRESLQYEYIRHRILQVRYLGEKLKEAGVPILEPVGG
[0134] HAVFLDARRFCSHIPQEEFPAQALAAAIYVECGVRTMERGIISAGRDVKTGENHKPKLETVRVTIPRRVYTYKHMDVVADGIIKLYKHKEDIKPLEFVYEPKQLRFFTARFGIKK*
[0135] TPL nucleotide sequence (SEQ ID NO.9)
[0136] ATGCGTTTTGAAGATTACCCGGCCGAACCGTTTCGTATTAAGAGTGTTGAAACCGTTAAAATGATCGAT
[0137] AAAGCAGCACGCGAAGAAGTTATTAAGAAAGCAGGTTATAACACCTTTCTGATTAATAGCGAAGATGTG
[0138] TATATCGATCTGCTGACCGATAGCGGCACCAATGCAATGAGTGATAAACAGTGGGGTGGCCTGATGCAG
[0139] GGCGATGAAGCATACGCTGGCAGTCGTAATTTCTTTCATCTGGAAGAAACCGTGAAAGAAATTTTTGGC
[0140] TTTAAACATATCGTGCCGACCCATCAGGGTCGTGGCGCAGAAAATATTCTGAGTCAGATTGCCATTAAG
[0141] CCGGGTCAGTATGTTCCGGGTAATATGTATTTTACCACCACCCGCTATCATCAGGAACGTAATGGCGGT
[0142] ATTTTTAAAGATATTATCCGTGATGAGGCACATGATGCCACCCTGAATGTTCCGTTTAAAGGTGACATT
[0143] GATCTGAATAAGCTGCAGAAACTGATTGATGAAGTGGGCGCAGAAAACATTGCATACGTTTGTCTGGCC
[0144] GTGACCGTGAATCTGGCAGGTGGTCAGCCGGTGAGTATGAAAAATATGAAAGCAGTGCGCGAACTGACC
[0145] AAAAAACATGGCATTAAGGTGTTTTATGACGCCACCCGCTGTGTGGAAAATGCCTATTTTATTAAGGAA
[0146] CAGGAAGAAGGCTATCAGGATAAAACCATTAAGGAAATTGTGCATGAAATGTTTAGCTATGCCGATGGT
[0147] TGTACCATGAGTGGTAAAAAAGATTGTCTGGTTAATATCGGCGGCTTTCTGTGTATGAATGATGAAGAT
[0148] CTGTTTCTGGCCGCCAAAGAAATTGTTGTGGTTTATGAAGGCATGCCGAGTTATGGTGGCCTGGCAGGT
[0149] CGTGATATGGAAGCAATGGCCATTGGTCTGCGCGAAAGTCTGCAGTATGAATATATTCGTCATCGCATT
[0150] CTGCAGGTTCGCTATCTGGGTGAAAAACTGAAAGAAGCAGGCGTGCCGATTCTGGAACCGGTTGGTGGT
[0151] CATGCAGTGTTTCTGGATGCCCGTCGTTTTTGCCCGCATATTCCGCAGGAAGAATTTCCGGCCCAGGCC
[0152] CTGGCAGCAGCAATCTATGTTGAATGCGGTGTTCGTACAATGGAACGTGGTATTATTAGCGCCGGCCGT
[0153] GATGTTAAAACCGGTGAAAATCATAAACCGAAACTGGAAACCGTGCGCGTGACCATTCCGCGCCGTGTT
[0154] TATACCTATAAACACATGGATGTTGTTGCCGAAGGCATTATTAAGCTGTATAAACATAAGGAAGACATC
[0155] AAACCGCTGGAATTTGTTTATGAACCGAAACAGCTGCGTTTCTTTACCGCCCGCTTTGGCATTAAGAAA
[0156] TAA。
Claims
1. A tyrosine phenol lyase mutant, characterized in that: The amino acid sequence shown in SEQ ID NO.1 is mutated, and the mutated amino acid site is at least one of A26V, R145C, E147V, E425D, and P357S.
2. The mutant according to claim 1, characterized in that: The mutants include any one of the following seven: A26V; R145C; P357S; E147V+E425D; E147V+E425D+A26V; E147V+E425D+R145C; E147V+E425D+P357S; Preferred: any one of E147V+E425D, E147V+E425D+A26V, A26V, E147V+E425D+P357S; Further preferred: E147V+E425D or E147V+E425D+A26V.
3. A polynucleotide encoding the tyrosine phenol-lyase mutant according to claim 1 or 2.
4. A vector comprising the polynucleotide of the tyrosine phenol-lyase mutant according to claim 3.
5. A host containing the vector according to claim 4.
6. The use of the tyrosine phenol lyase mutant according to claim 1 or 2, characterized in that: Used for catalytic preparation of levodopa.
7. The use according to claim 6, characterized in that: In each 500mL reaction system, the amount of crude tyrosine phenol lyase solution added is 20-60g / L, and the corresponding enzyme activity is 3000-9000U.
8. The use according to claim 6 or 7, characterized in that: In the reaction system, the concentration of PLP is 0.1-0.2 g / L, the concentration of sodium sulfite is 0.5-6 g / L, the concentration of ammonium acetate is 50-280 g / L, the concentration of sodium pyruvate is 40-220 g / L, the concentration of catechol is 40-220 g / L, and the concentration of disodium EDTA is 1-2 g / L.
9. The use according to claim 6 or 7, characterized in that: The reaction temperature is 20-30°C and the reaction time is 5-22h.
10. The use according to claim 6 or 7, characterized in that: The reaction pH is 7.5-8.5.
Citation Information
Cited By
Mycobacterium tuberculosis tyrosine phenol lyase mutant and application thereof
CN119859627A
A mutant of Mycobacterium tuberculosis tyrosine phenol lyase and its application
CN119859627B
Construction method and application of engineering bacteria for efficiently expressing tyrosine phenol lyase mutant
CN120330173A
A method for constructing an engineered bacterium that efficiently expresses a tyrosine phenol lyase mutant and its application
CN120330173B
Phenol-resistant tyrosine phenol lyase mutant and application thereof
CN121495912A
